Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ammonia Solution, Strong. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8587303 | 0.95 | ALDH1A1 (0.42) | — | |
| Water SCHEMBL3706340 | 0.95 | — | — | |
| Ammonia Solution, Strong SCHEMBL4884987 | 0.95 | — | — | |
| Ammonia Solution, Strong SCHEMBL28215682 | 0.90 | — | — | |
| SCHEMBL285 | 0.89 | — | — | |
| SCHEMBL18185998 | 0.89 | ALDH1A1 (0.46) | — | |
| SCHEMBL5084531 | 0.89 | — | — | |
| Fluoride SCHEMBL9698194 | 0.89 | — | — | |
| SCHEMBL145743 | 0.89 | — | — | |
| Hydrazine SCHEMBL20766052 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843299-A | Synthesis of oligonucleotides and related compounds | 詹森生物制药有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-6300486-B1 | CONDENSING A NUCLEOSIDE HAVING ONE HYDROXYL END BEARING A H-PHOSPHONATE GROUP AND THE OTHER PROTECTED WITH POLYMER-BOUND NUCLEOSIDE HAVING FREE HYDROXYL END IN SOLVENT WHICH SWELLS POLYMER, DEPROTECTING, REPEATING, OXIDATION | ISIS PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | disclosed |
| US-5830881-A | L-2'3',dideoxy nucleoside analogs as anti-hepatitus B (HBV) agents | YALE UNIVERSITY (US) | 1998-11-03 | — | — | US | disclosed |
| US-5631239-A | VIRICIDES FOR HEPATITIS | YALE UNIVERSITY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5627160-A | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents | YALE UNIVERSITY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5561120-A | LOW TOXICITY TO HOST CELLS | YALE UNIVERSITY (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0707481-A4 | — | — | 1996-05-29 | — | — | EP | disclosed |
| EP-0707481-A1 | L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1994027616-A1 | L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1993017035-A1 | 2'ISODIDEOXY-β-D-NUCLEOSIDES AS STABLE ANTIVIRAL AGENTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-09-02 | — | — | WO | disclosed |
| US-5231174-A | 2'isodideoxy-β-D-nucleosides as stable antiviral agents | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-07-27 | — | — | US | disclosed |
| US-5204455-A | Monomethoxytrityl protected oligonucleotides bound to a solid support | ISIS PHARMACEUTICALS, INC. | 1993-04-20 | — | — | US | disclosed |
| US-5164491-A | Large scale synthesis of oligonucleotides and their associated analogs | GILEAD SCIENCES (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0361831-B1 | ANTIVIRAL NUCLEOSIDE COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-01-22 | — | — | EP | disclosed |
| EP-0361831-A1 | Antiviral nucleoside combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0163405-A2 | Method of rate enhancement for triester synthesis of oligonucleotides using a catalytic alcohol, and compounds for use therein | GENENTECH, INC. (US) | 1985-12-04 | — | — | EP | disclosed |